Oncology pipeline
We are committed to transforming the lives of people with cancer through innovative therapies. Our robust pipeline spans cancer cell–directed and immuno-oncology investigational therapies. Through global collaboration, we are tackling some of the most challenging, but potentially most impactful, areas of cancer research.
Latest development phase
As of September, 2025
Cancer cell directed
Phase I
Recruiting
Solid tumors (Phase Ia) and NSCLC (Phase Ib)
(Recruiting for cohorts 7 and 8 only)
Phase II*
Recruiting
Solid tumors, breast cancer, gastric adenocarcinoma, GEJ adenocarcinoma and esophageal adenocarcinoma
± combination
T-cell engagers
Phase I
Recruiting
Solid tumors, colorectal carcinoma, gastric carcinoma and PDAC
± combination
Cancer vaccines and oncolytic viruses
Compound/target
KISIMA® cancer vaccine
(ATP150/ATP152/ATP162 and VSV-GP154)21
Immuno-modulators
Phase I
Recruiting
Solid tumors and HNSCC
(Recruiting for Phase Ib)
± combination
Phase I
Recruiting
Solid tumors and HNSCC
(Recruiting for Phase Ib)
± combination
*Beamion™ BCGC-1 is a Phase I/II trial; †1438-0002 is a Phase I/II trial.
Download a summary of ongoing clinical trials
-
Heymach JV, et al. J Clin Oncol 2025;43(11):1337–1347.
-
Heymach JV, et al. N Engl J Med 2025;392(23):2321–2333.
-
ClinicalTrials.gov. NCT04886804. https://clinicaltrials.gov/study/NCT04886804 (Accessed: August 2025).
-
ClinicalTrials.gov. NCT06151574. https://clinicaltrials.gov/study/NCT06151574 (Accessed: August 2025).
-
ClinicalTrials.gov. NCT06581432. https://clinicaltrials.gov/study/NCT06581432 (Accessed: August 2025).
-
Schram AM, et al. J Clin Oncol 2025;43(16). Abstract TPS3187.
-
ClinicalTrials.gov. NCT06324357. https://clinicaltrials.gov/study/NCT06324357 (Accessed: July 2025).
-
Nakayama I, et al. J Clin Oncol 2025;43(4). Abstract TPS509.
-
Hurvitz SA, et al. ESMO Open 2025;10(S4). Abstract 409TiP.
-
ClinicalTrials.gov. NCT04429087. https://clinicaltrials.gov/study/NCT04429087 (Accessed: August 2025).
-
Wermke M, et al. J Clin Oncol 2025;43(27):3021–3031.
-
ClinicalTrials.gov. NCT05879978. https://clinicaltrials.gov/study/NCT05879978 (Accessed: August 2025).
-
ClinicalTrials.gov. NCT05882058. https://clinicaltrials.gov/study/NCT05882058 (Accessed: September 2025).
-
ClinicalTrials.gov. NCT06132113. https://clinicaltrials.gov/study/NCT06132113 (Accessed: August 2025).
-
ClinicalTrials.gov. NCT06077500. https://clinicaltrials.gov/study/NCT06077500 (Accessed: August 2025).
-
ClinicalTrials.gov. NCT05990738. https://clinicaltrials.gov/study/NCT05990738 (Accessed: August 2025).
-
Wermke M, et al. ASCO 2025. Poster 8094.
-
ClinicalTrials.gov. NCT06091930. https://clinicaltrials.gov/study/NCT06091930 (Accessed: August 2025).
-
Doi T, et al. J Clin Oncol 2024;42(16_suppl). Abstract TPS2669.
-
ClinicalTrials.gov. NCT06882746. https://clinicaltrials.gov/study/NCT06882746 (Accessed: July 2025).
-
ClinicalTrials.gov. NCT05846516. https://clinicaltrials.gov/study/NCT05846516 (Accessed: September 2025).
-
ClinicalTrials.gov. NCT05155332. https://clinicaltrials.gov/study/NCT05155332 (Accessed: August 2025).
-
Shroff RT, et al. Cancer Res 2025;85(8_Supplement_2). Abstract CT110.
-
ClinicalTrials.gov. NCT04958239. https://clinicaltrials.gov/study/NCT04958239 (Accessed: August 2025).
-
ClinicalTrials.gov. NCT05327946. https://clinicaltrials.gov/study/NCT05327946 (Accessed: July 2025).
-
Wang JS, et al. J Clin Oncol 2025;43(16_suppl). Abstract 2515.
-
ClinicalTrials.gov. NCT06806852. https://clinicaltrials.gov/study/NCT06806852 (Accessed: July 2025).
-
ClinicalTrials.gov. NCT05471856. https://clinicaltrials.gov/study/NCT05471856 (Accessed: August 2025).
CD, cluster of differentiation; DLL3, Delta-like ligand 3; epNEC, extrapulmonary neuroendocrine carcinoma; FAP, fibroblast activation protein; GEJ, gastroesophageal junction; GP, glycoprotein; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; NEC, neuroendocrine carcinoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein-1; PDAC, pancreatic ductal adenocarcinoma; SCLC, small cell lung cancer; SIRPα, signal-regulatory protein alpha; STING, small molecule agonist of the stimulator of interferon genes; TcE, T-cell engager; TKI, tyrosine kinase inhibitor; VSV, vesicular stomatitis virus.